Home > Products > doxorubicin & EGFR > Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scIgG)

Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scIgG)  (CAT#: SCIGG-151)

Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-doxorubicin and anti-EGFR IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can be used in pretargeting system and deliver toxin to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Datasheet INQUIRY

Specifications

Targets
doxorubicin & EGFR
Type
Single chain IgGs
Species Reactivity
Human
Application
FuncS; Pretargeting system for toxin delivery
Related Disease
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors

Targets

Target 1
doxorubicin
Alternative Names
doxorubicin
Target 2
EGFR
Gene ID
UniProt ID
Alternative Names
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "doxorubicin & EGFR"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-doxorubicin x Anti-EGFR Bispecific Antibody (scIgG) (SCIGG-151). Click the button below to contact us or submit your feedback about this product.